Workflow
varoglutamstat
icon
Search documents
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025
Globenewswire· 2025-08-27 05:00
Core Insights - Vivoryon Therapeutics N.V. will report its H1 2025 financial results and operational progress on September 4, 2025 [1] - The company focuses on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases [3] Financial Reporting - The financial results will cover the period ended June 30, 2025, and will be available for download on the company's website [1] - A conference call and webcast will be held on the same day to discuss the results [2] Company Overview - Vivoryon is a clinical stage biotechnology company dedicated to innovative treatments for kidney-related inflammatory and fibrotic disorders [3] - The company's leading program, varoglutamstat, is a first-in-class orally available QPCT/L inhibitor aimed at treating diabetic kidney disease [3]
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences
Globenewswire· 2025-06-27 05:00
Group 1 - Vivoryon Therapeutics N.V. is a clinical stage biotechnology company focused on developing small molecule medicines for inflammatory and fibrotic disorders, primarily targeting kidney diseases [2][3] - The company will present at two upcoming investor conferences: the mwb online Health Care Conference on July 1, 2025, and the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025 [1][2] - The management team attending these conferences includes Frank Weber, CEO, and Julia Neugebauer, COO [1][2] Group 2 - Vivoryon's most advanced program, varoglutamstat, is a proprietary, first-in-class orally available QPCT/L inhibitor being evaluated for the treatment of diabetic kidney disease [2] - The company aims to improve patient outcomes by modulating the activity and stability of pathologically relevant proteins [2]
Vivoryon Therapeutics N.V. Reports Outcome of 2025 Annual General Meeting
Globenewswire· 2025-06-24 13:00
Core Points - Vivoryon Therapeutics N.V. held its Annual General Meeting (AGM) on June 24, 2025, where shareholders approved all agenda items, including the appointment of Dr. Julia Neugebauer as an executive director [2] - The re-appointment of Dr. Frank Weber and Anne Doering as executive directors, along with the re-appointment of Dr. Erich Platzer, Charlotte Lohmann, Dr. Claudia Riedl, and Dr. Samir Shah as non-executive directors, was also confirmed [2] Company Overview - Vivoryon is a clinical stage biotechnology company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly diabetic kidney disease [3] - The company's leading program, varoglutamstat, is a proprietary, first-in-class orally available QPCT/L inhibitor aimed at treating diabetic kidney disease [3]
Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress
Globenewswire· 2025-06-17 05:00
Core Insights - Vivoryon Therapeutics N.V. reported its Q1 2025 financial results and operational progress, focusing on the development of varoglutamstat for kidney diseases, particularly diabetic kidney disease (DKD) [2][3] Financial Performance - Revenues for Q1 2025 were zero, consistent with Q1 2024 [14] - Research and development expenses decreased by EUR 6.2 million to EUR 1.2 million in Q1 2025 from EUR 7.4 million in Q1 2024, primarily due to lower third-party expenses [14][16] - General and administrative expenses were EUR 1.3 million in Q1 2025, down from EUR 2.1 million in Q1 2024 [16] - Net loss for Q1 2025 was EUR 2.5 million, compared to EUR 9.3 million in Q1 2024 [17] - Cash and cash equivalents as of March 31, 2025, were EUR 7.0 million, down from EUR 9.4 million as of December 31, 2024 [17] Clinical Development - The company is advancing varoglutamstat in kidney disease, with a planned Phase 2b study in DKD as a priority for 2025 [9] - A meta-analysis confirmed that varoglutamstat at 600mg twice daily significantly improved eGFR kidney function, with effects sustained until week 96 [7] - Preclinical data showed a synergistic effect of varoglutamstat in combination with SGLT-2 inhibitors, indicating potential for enhanced treatment regimens [5][6] Intellectual Property - A new composition of matter patent for varoglutamstat was granted in the U.S., providing exclusivity through 2044, with potential extensions [10] - The company is actively pursuing additional patents related to varoglutamstat and its applications in kidney disease [10] Corporate Developments - Vivoryon entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors for up to EUR 15 million in ordinary shares over the next 36 months, enhancing financial flexibility [12] - Julia Neugebauer was appointed as Chief Operating Officer, effective May 1, 2025, to oversee investor relations and corporate functions [13] Pipeline Updates - The company has nominated a new candidate, VY2149, a next-generation QPCT/L inhibitor, expected to enter late-stage preclinical development [11]
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025
Globenewswire· 2025-06-11 05:00
Core Viewpoint - Vivoryon Therapeutics N.V. is set to report its Q1 2025 financial results and operational progress on June 17, 2025, focusing on its development of small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases [1][3]. Group 1: Financial Results Announcement - The company will publish its first quarter financial results for the period ended March 31, 2025, on June 17, 2025 [1]. - A corporate update will accompany the financial results announcement [1]. Group 2: Conference Call Details - A conference call will be held on June 17, 2025, at 3:00 pm CEST / 9:00 am EDT, available via phone and webcast [2]. - Participants are encouraged to pre-register for the call to receive dedicated dial-in details and should join 15 minutes early to avoid delays [2]. Group 3: Company Overview - Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for treating inflammatory and fibrotic disorders of the kidney [3]. - The company's leading program, varoglutamstat, is a first-in-class orally available QPCT/L inhibitor being evaluated for diabetic kidney disease [3].
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025
Globenewswire· 2025-06-06 07:45
Core Insights - Vivoryon Therapeutics N.V. presented meta-analysis data for its lead drug varoglutamstat at the 62nd ERA Congress, highlighting significant improvements in kidney function [1][2][3] Group 1: Drug Development and Efficacy - Varoglutamstat is a first-in-class glutaminyl cyclase (QPCT/L) inhibitor with notable anti-inflammatory and anti-fibrotic effects [3] - The Phase 2 studies, VIVIAD and VIVA-MIND, demonstrated statistically significant and clinically meaningful improvements in estimated glomerular filtration rate (eGFR) in elderly patients, with effects sustained from week 24 to week 96 [3] - The meta-analysis indicated a larger effect size in participants with diabetes compared to those without [3] Group 2: Future Plans - The next step involves a dedicated Phase 2b trial focusing on patients with diabetic kidney disease, aiming to assess efficacy on eGFR and gather data on proteinuria and other kidney-specific markers [4] Group 3: Presentation Details - The presentation took place on June 6, 2025, at 8:15 am CEST in Vienna, Austria, led by Frank Weber, CEO of Vivoryon Therapeutics [5]
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat
Globenewswire· 2025-05-27 05:00
Core Viewpoint - Vivoryon Therapeutics N.V. has been granted a new U.S. patent for its lead drug varoglutamstat, enhancing its intellectual property portfolio and supporting its development strategy in kidney disease [2][3][7]. Group 1: Patent Details - The newly granted U.S. composition of matter patent (US 12,312,335) covers the only polymorph of the salt form used in varoglutamstat, with a patent term extending through 2044 and potential extension to 2049 under the Hatch-Waxman Act [3][4]. - The patent was granted after an accelerated examination process, indicating the efficiency and effectiveness of the company's patent application strategy [2][3]. Group 2: Strategic Focus - Vivoryon is actively pursuing additional patents related to varoglutamstat and its applications in kidney disease, including medical use and dosing regimens, both as monotherapy and in combination with SGLT-2 inhibitors [4][5]. - The company has filed multiple patents in the past months, reflecting its commitment to strengthening its intellectual property in the field of kidney diseases [4][5]. Group 3: Broader Patent Portfolio - Vivoryon has developed a robust patent portfolio for QPCT/L inhibitors, encompassing over 20 patent families and more than 400 patent applications and issued patents across major markets [6]. - The majority of the patents focus on composition of matter for QPCT/L inhibitors, with recent applications emphasizing the company's focus on kidney diseases and the synergistic effects observed in preclinical research [5][6].